Rigel Pharmaceuticals (RIGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 8,654 | 367,024 | 98,959 | 71,059 | 11,446 |
| Depreciation Amortization | 427 | 1,265 | 907 | 771 | 414 |
| Income taxes - deferred | 2,573 | -245,852 | N/A | N/A | N/A |
| Accounts receivable | 1,818 | -10,148 | -4,310 | 1,708 | 68 |
| Accounts payable and accrued liabilities | -2,705 | 3,852 | 507 | 3,951 | 615 |
| Other Working Capital | -12,385 | -19,512 | -16,173 | -8,805 | -16,077 |
| Other Operating Activity | 4,343 | -20,974 | -26,215 | -39,040 | 2,641 |
| Operating Cash Flow | $2,725 | $75,655 | $53,675 | $29,644 | $-893 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -7,975 | -92,365 | -66,991 | -33,828 | -10,552 |
| PPE Investments | N/A | N/A | -12 | N/A | N/A |
| Investing Cash Flow | $-7,975 | $-92,365 | $-67,003 | $-33,828 | $-10,552 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -7,500 | -7,500 | N/A | N/A | 0 |
| Common Stock Issued | 321 | 8,101 | 5,173 | 902 | 484 |
| Common Stock Repurchased | -3,740 | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $-10,919 | $601 | $5,173 | $902 | $484 |
| Beginning Cash Position | 40,637 | 56,746 | 56,746 | 56,746 | 56,746 |
| End Cash Position | 24,468 | 40,637 | 48,591 | 53,464 | 45,785 |
| Net Cash Flow | $-16,169 | $-16,109 | $-8,155 | $-3,282 | $-10,961 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,725 | 75,655 | 53,675 | 29,644 | -893 |
| Capital Expenditure | N/A | N/A | -12 | N/A | N/A |
| Free Cash Flow | 2,725 | 75,655 | 53,663 | 29,644 | -893 |